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LESSONS LEARNED
• The levels of circulating follicle-stimulating hormone, luteinizing hormone, estriol, estradiol, and estrone remained
unchanged after a 12-week treatment with 0.005% estriol vaginal gel in postmenopausal women receiving nonsteroidal
aromatase inhibitors for hormone receptor-positive early breast cancer.
• These results support the safety of 0.005% estriol vaginal gel for the treatment of bothering symptoms of vulvovaginal
atrophy in breast cancer survivors.
• The results provide clinicians with confidence in the use of this product in women who do not experience symptom relief
with nonhormonal remedies.
ABSTRACT
Background. Symptoms of vulvovaginal atrophy associated
with treatment with nonsteroidal aromatase inhibitors (NSAIs)
negatively impact patients’ quality of life and may affect adher-
ence to NSAIs. Vaginal estrogens effectively improve these
symptoms, although their safe use in breast cancer survivors
remains unclear.
Methods. Postmenopausal women with hormone receptor-
positive early breast cancer receiving NSAI and moderate-
to-severe vaginal dryness were randomized to 0.005% estriol
vaginal gel or placebo for 12 weeks. Circulating estrogens,
follicle-stimulating hormone (FSH), and luteinizing hormone
(LH), were analyzed at baseline and at weeks 1, 3, 8, and 12.
The primary safety outcome was the variation in serum FSH
from baseline to week 12.
Results. Sixty-one women (mean age, 59 years) enrolled in
the study. Small oscillations were observed in FSH and LH,
although they were always maintained within the postmeno-
pausal range. No significant differences were found in the vari-
ation of FSH and LH between baseline and week 12 from the
physiological variation observed before treatment. Women
receiving 0.005% estriol vaginal gel had slightly increased
estriol levels at weeks 1 and 3, with a subsequent reduction
until normalizing at week 12; estradiol and estrone remained
the below limit-of-quantitation in almost all samples.
Conclusion. Ultralow-dose 0.005% estriol vaginal gel did
not significantly influence estrogens, FSH, and LH levels in
women with breast cancer receiving NSAI. A transient neg-
ligible absorption of estriol and a nonsignificant variation
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Clinical Trial Results
of FSH after 12 weeks were observed. These findings pro-
vide confidence for the safe use of 0.005% estriol vaginal
gel in women with breast cancer with an indication for
treatment with vaginal estrogens. The Oncologist
2020;25:e1846–1854
DISCUSSION
Breast cancer survivors who are receiving adjuvant therapywith
NSAIs have to deal with a constellation of genitourinary symp-
toms, including but not limited to dryness, burning, and
dyspareunia, associated with vulvovaginal atrophy (VVA)
[1, 2]. Although not severe, the long-lasting nature of these
symptoms negatively affects the patient’s quality of life and
may even jeopardize adherence to adjuvant endocrine therapy
[3, 4]. Althoughmoisturizers and lubricantsmay provide tempo-
rary relief of VVA symptoms, most women require local
hormonal treatments [1–3]. These treatments have proven effi-
cacy in reversing VVA associated with estrogen depletion; how-
ever, their use in breast cancer survivors has raised safety
concerns because of the need for keeping serum estrogens
depressed.
Under the hypothesis that an ultralow-dose estriol vaginal
gel would not affect the serum levels of gonadotropin hor-
mones, we randomized 61 NSAI-treated breast cancer survivors
to receive either 0.005% estriol vaginal gel (n = 50) or placebo
moisturizing gel (n = 11). Owing to the high variability of FSH
and LH levels between screening (study enrollment) and base-
line (immediately before treatment start), the primary endpoint
was based on the differences between physiological variability
(i.e., screening vs. baseline) and treatment variability
(i.e., mean of screening and baseline vs. given time point).
After 12 weeks of treatment, no significant differences were
observed between physiological and treatment variability of
FSH levels in the active group (median, −2.8 mIU/mL; inter-
quartile range [IQR], −13.1 to 7.4; p = .104) or in the placebo
group (median, 1.4; IQR, −5.4 to 15.7; p = .413; Fig. 1). These
results were reinforced by the lack of significant differences
between treatment arms in the absolute values of serum FSH:
median, 51.0 mIU/mL (IQR, 38.6 to 63.5) and 62.1 (46.8 to
90.1) for active and placebo groups, respectively (p = .078). This
trendwas also observed in LH levels, except forweek 12,where
median (IQR) differences between physiological variability and
treatment variability were − 0.8 (−5.3 to 2.9) and 1.3 (−1.6
to 7.1) mlU/mL for active and placebo groups, respec-
tively (p = .025).
Consistent with the decline in absorption of vaginal estro-
gens with epithelium maturation [5, 6], estriol levels were
higher in the active group within the first 3 weeks but
decreased throughout treatment, reaching similar levels at
week 12: median (IQR), 0.5 (0.5 to 7.3) and 0.5 (0.5 to 0.5) for
active and placebo group, respectively (p = .140). As expected,
the serum levels of estradiol and estrone remained below the
limit of quantification at baseline and at all time points for
both active and placebo groups.
In summary, our results provide confidence in the safe
use of ultralow-dose 0.005% estriol vaginal gel in breast
cancer survivors treated with NSAIs. The application of the
gel has a negligible impact on the systemic levels of estro-
gens, FSH, and LH in these patients, whereas the proven
efficacy in symptom relief may improve compliance with




Stage of Disease/Treatment Adjuvant
Prior Therapy No designated number of regimens
Type of Study Phase II, randomized
Primary Endpoint Safety
Figure 1. Box-plot of the FSH and LH values determined at each of the indicated visits in the active and placebo groups (intention-
to-treat population). (A): FSH levels. (B): LH levels.
Abbreviations: FSH, follicle-stimulating hormone; LH, luteinizing hormone.
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Study Design and Population
This was a phase II, randomized, double-blind, placebo-controlled, international, multicenter trial for assessing safety and efficacy of
0.005% estriol vaginal gel in the treatment of vaginal dryness in postmenopausal women with breast cancer experiencing VVA. The
study included patients with hormone receptor-positive (and any HER2 status) early breast cancer (stage I–IIIA) treated with NSAIs
(either anastrozole or letrozole) for at least 6 months. Participants were recruited from five Spanish sites and one site in Sweden.
Patients had to report vaginal dryness, either moderate (i.e., bothersome and annoying) or severe (i.e., bothersome, annoying, and
interfered with normal daily activity). Other inclusion criteria were a score 0–1 in the Eastern Cooperative Oncology Group perfor-
mance status (ECOG) and an adequate bone marrow and organ function. Patients with vaginal bleeding of unknown etiology and
endometrial thickness ≥ 4 mm were excluded. A full list of selection criteria is provided in supplemental Online File 1. All patients
signed an informed consent before treatment. The study protocol was approved by the regulatory authorities and applicable ethics
committees of the participating countries.
Intervention
The study was conducted in two phases: the safety phase and the study phase. During the safety phase, a sentinel group of
10 women were treated daily for 3 weeks with active treatment (0.005% estriol vaginal gel, study drug) or placebo (moistur-
izing gel) at a 4:1 ratio. After verifying no influence of treatment on either the levels of systemic estrogens or gonadotropins
in sentinel participants, a minimum of 60 women (study group) were randomized to receive either active treatment or pla-
cebo at a 4:1 ratio. The study drug and placebo had identical characteristics (appearance, smell, and texture), and the investi-
gators and patients were blinded to randomization codes.
Both treatments were administered using an intravaginal applicator at the dose of 1 g of gel per application (containing
50 mg of estriol for the active treatment) for 12 weeks: once daily during the first 3 weeks and twice weekly during weeks
4–12. The baseline visit was scheduled within 2 weeks after the screening visit. Follow-up visits were performed at weeks
1, 3, 8, and 12 of treatment and 30  5 days after the last study drug dose (post-treatment visit). Treatment compliance was
assessed by counting and recording the number of unused applicators.
Safety Assessments
The primary endpoint was the change in serum levels of FSH from baseline toweek 12. Secondary endpoints regarding safety included
the variation of serum levels of FSH, LH, and plasma levels of estrogens (estriol, estradiol, and estrone) throughout treatment. Estrogen
determinations were performed at a central laboratory (Pharm-Analyt, Baden Austria) at baseline and weeks 1, 3, 8, and 12. Owing to
the extremely low levels of estrogens expected, the concentration of estriol, estradiol, and estrone was determined using a newly
developed and validated ultrasensitive liquid chromatography-tandemmass spectrometry method. Values below the limit of quantifi-
cation (LOQ) were considered as 0.5 pg/mL for estriol, 1.5 pg/mL for estradiol, and 2.5 pg/mL for estrone. FSH and LH were deter-
mined at the same time points and additionally at screening visit to assess their physiological variability and analyzed by
chemiluminescent immunoassay at Laboratorios Echevarne (Barcelona, Spain). Other safety assessments included laboratory assess-
ments (hematology, blood chemistry, and urine tests) and a physical and gynecological examination (breast and pelvic examination)
performed at baseline and at weeks 3 and 12. Endometrial examination was performed by ultrasound at baseline and week 12. All
adverse events were recorded, and the causal relationship between the investigational product and the event was assessed [7].
Statistics
All the analyses were performed on the intention-to-treat population, which included all randomized patients unless other-
wise specified. Categorical variables were presented as frequency and percentage, whereas quantitative variables were pres-
ented as the mean and SD or the median and interquartile range (IQR). The differences between pretreatment variability
(i.e., screening vs. baseline) of hormone levels and treatment variability (i.e., mean of screening and baseline vs. given
assessment point) were analyzed using the Wilcoxon signed-rank test, and the between-group differences regarding the
change in hormone levels were analyzed using the nonparametric Mann-Whitney-Wilcoxon test. Based on FSH levels in
patients treated with NSAIs reported by Pfeiler et al. [8], a sample size of 44 patients was considered to provide 80% power
to detect a decrease of FSH levels from 75.7 to 66.0 mIU/mL, assuming an SD of 22.3 and with an α level of 0.05. All analyses
were performed using the statistical software SAS Enterprise Guide 5.1 (SAS Institute, Cary, NC).
Investigator’s Analysis Active and should be pursued further
DRUG INFORMATION
Drug 1
Generic/Working Name Ultralow-dose 0.005% estriol vaginal gel
Trade Name Blissel, Gelistrol, or Gelisse
Drug Type Small molecule
Drug Class Hormone analog
Dose 50 μg per
Route Vaginal
Schedule of Administration 1 g of gel per application (containing 50 mg of estriol for the
active treatment arm) for 12 weeks: once daily during the first
3 weeks, and twice weekly during weeks 4–12
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Drug 2
Generic/Working Name Moisturizing gel
Trade Name Ainara
Route Vaginal
Schedule of Administration 1g of gel per application for 12 weeks: once daily during the
first 3 weeks, and twice weekly during weeks 4–12
PATIENT CHARACTERISTICS: PLACEBO
Number of Patients, Male 0
Number of Patients, Female 11
Breast Cancer Stage Stage I: 4 (36.4%)
Stage IIA: 3 (27.3%)
Stage IIB: 2 (18.2%)
Stageg IIIA: 2 (18.2%)
Age Median (range): 63 years (52–66 years)





Previous Adjuvant Hormone Treatments Aromatase inhibitors: 10 (90.9%)
Aromatase inhibitors + tamoxifen: 1 (9.1%)
Aromatase inhibitors + tamoxifen +luteinizing hormone-
releasing hormone (LHRH) agonist: 0 (0.0%)
Cancer Types or Histologic Subtypes Estrogen receptor-positive, 11; progesterone receptor-positive,
9; HER2-positive, 3.
PATIENT CHARACTERISTICS: EXPERIMENTAL
Number of Patients, Male 0
Number of Patients, Female 50
Breast Cancer Stage Stage I: 18 (36.0%)
Stage IIA: 23 (46.0%)
Stage IIB: 7 (14.0%)
Stage IIIA: 2 (4.0%)
Age Median (range): 58.5 years (45–77 years)





Previous Adjuvant Hormone Treatments Aromatase inhibitors: 41 (82.0%)
Aromatase inhibitors + tamoxifen: 8 (16.0%)
Aromatase inhibitors + tamoxifen + LHRH agonist: 1 (2.0%)
Cancer Types or Histologic Subtypes Estrogen receptor-positive, 50; progesterone receptor-positive,
38; HER2-positive, 13.
PRIMARY ASSESSMENT METHOD
Title Change in serum levels of FSH
Number of Patients Screened 86
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Number of Patients Enrolled 61
Number of Patients Evaluable for Toxicity 61
Number of Patients Evaluated for Efficacy 61
Evaluation Method Determination of FSH
Outcome Notes The primary outcome was the change in serum levels of FSH,
shown in Table 2.
ADVERSE EVENTS
The frequency of each adverse event is provided in Table 3.
ASSESSMENT, ANALYSIS, AND DISCUSSION
Completion Study completed
Investigator’s Assessment Active and should be pursued further
In this phase II, randomized, double-blind, placebo-
controlled clinical trial, we investigated the safety of 0.005%
estriol vaginal gel for the treatment of symptoms of vul-
vovaginal atrophy in postmenopausal women receiving
nonsteroidal aromatase inhibitors (NSAIs) for hormone recep-
tor-positive early breast cancer in terms of the impact of vaginal
treatment on the levels of serum gonadotropins. The analysis
included 61 women (Fig. 2), all of them with menopausal sta-
tus, achieved either by spontaneous amenorrhea or because of
an oophorectomy (Table 1). Patients were randomized 4:1,
with 50 in the treatment group and 11 in the placebo group.
One of the major barriers for the analysis of the primary
objective (i.e., the influence of estriol treatment on the serum
levels of gonadotropins) was the high physiological variability of
the serum follicle-stimulating hormone (FSH) and luteinizing
hormone (LH), which in our study ranged from 18.6 to
132 mIU/mL and from 4.3 to 93 mIU/mL, respectively. This vari-
ability in serum levels was consistent with those reported previ-
ously [9] and slightly higher than the postmenopausal range
typically considered for FSH and LH (21.7–153 mIU/mL and
11.3–39.8 mIU/mL for FSH and LH, respectively). Based on the
physiological variability of gonadotropin levels observed in our
cohort, we deemed the comparative analysis of the variation of
the pretreatment and during treatment ranges the most accu-
rate strategy to capture this variability and minimize its con-
founding effects. During therapy with 50 μg vaginal estriol,
small differences between physiological variability and treat-
ment variability of FSH were found at weeks 1 and 3 but not at
subsequent visits (Table 2). At week 12 (primary endpoint), no
significant differences were observed between physiological
and treatment variability of FSH levels (p = .104; Wilcoxon
signed-rank test). The variability of LH levels throughout treat-
ment was persistently comparable to the physiological variabil-
ity. These results were reinforced by the lack of significant
differences between active and placebo groups regarding the
changes in pretreatment and treatment variability of FSH levels
(p > .1 for differences in variability changes [pretreatment
vs. treatment] between active and placebo groups at all follow-
up visits; Fig. 2). This trend was also observed in LH levels,
except for week 12, where median (interquartile range [IQR])
differences between physiological variability and treatment
variability were -0.8 (−5.3 to 2.9) and 1.3 (−1.6 to 7.1) mlU/mL
for active and placebo groups, respectively (p = .025).
The serum levels of estradiol and estrone were not affected
by the vaginal treatment, and both hormones remained within
the expected postmenopausal ranges in both study groups. In
contrast, a transient and minimal absorption of estriol was
observed at the beginning of treatment. Estriol is a much wea-
ker estrogen than estradiol and displays a preferential affinity
to β (urogenital) rather than α (breast) estrogen receptors [10,
11]. Furthermore, pharmacokinetic analyses have shown very
limited absorption in healthy postmenopausal women, which
tend to decrease as the vaginal epithelium matures within a
short time following the start of the vaginal treatment [5,
12]. Based on these pharmacodynamic and pharmacokinetic
characteristics, various authors have supported vaginal estriol
over estrogen in patients with adjuvant therapy for breast can-
cer [3]. Nevertheless, to date, the safety of this approach has
only been assessed in general postmenopausal women [13] or
short series (10–16 subjects) of breast cancer survivors under
adjuvant therapy, who used vaginal tablets containing
0.5–0.03 mg of estriol [14, 15]. In our cohort, serum estriol
transiently raised within the first 3 weeks, with the highest
levels observed at week 1 after treatment start. However,
estriol levels at that time point (median, 3.9 pg/mL; IQR,
0.5–12.1) were much lower than the active threshold of
288 pg/mL reported in in vitro analyses [16]. Furthermore,
unlike previous experiences with higher concentrations of vagi-
nal estriol, which reported a small and transient decrease in
gonadotropin levels [14, 15], the variation of FSH and LH in our
analysis remained within the physiological range and equiva-
lent to that of patients in the placebo group. These findings,
together with a lack of recurrences reported in series of
women using hormone-based vaginal creams [14], suggest that
the small and transient increase in estriol after the firsts weeks
of ultralow-dose administration is unlikely to jeopardize the
therapeutic outcomes of adjuvant therapy.
In addition to the high physiological variability observed in
the serum levels of gonadotropins, which was overcome by ana-
lyzing the pretreatment and during-treatment variability, our
study was limited by the unbalanced country representative-
ness, with all centers being Spanish except one. Of note, this did
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not affect the laboratory tests, which were performed by two
central laboratories in Spain and Austria. Given that our results
indicate that the 0.005% estriol gel preparation is safe, the repli-
cation of the study using a larger sample size is warranted.
In summary, our results provide confidence in the safe use
of ultralow-dose 0.005% estriol vaginal gel in postmenopausal
breast cancer survivors treated with NSAIs. The application of
the ultralow-dose estriol vaginal gel has a negligible impact on
estrogens, FSH, and LH systemic levels in these patients, whereas
the proven efficacy of estriol in symptom relief may improve
compliance to adjuvant therapy in patients with breast cancer.
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FIGURE AND TABLES
Figure 2. Flow diagram of the patients included in the study.
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Table 2. Change in hormone levels between physiological variability (i.e., from screening to baseline) and treatment
variability (i.e., from mean screening-baseline to a given treatment point)
Hormone
Active Δ [physiological variability vs.
treatment variability]
Placebo Δ [physiological variability vs.
treatment variability]
FSH
Wk 1 −4.8 (−11.6 to 2.6)a 4.2 (−7.8 to 7.3)b
Wk 3 −4.2 (−12.0 to 3.5)a −0.9 (−4.0 to 2.3)b
Wk 8 −2.6 (−10.1 to 7.9)b 5.2 (−11.8 to 9.0)b
Wk 12 −2.8 (−13.1 to 7.4)c 1.4 (−5.4 to 15.7)c
LH
Wk 1 −0.6 (−3.7 to 2.8)b 0.2 (−1.8 to 8.1)b
Wk 3 −0.5 (−4.1 to 3.5)b 0.3 (−1.8 to 7.7)b
Wk 8 −0.3 (−4.9 to 3.1)b −1.3 (−2.0 to 6.0)b
Wk 12 −0.8 (−5.3 to 2.9)c 1.3 (−1.6 to 7.1)c
Results shown as median (interquartile range).
aSignificant difference based on the multiple comparisons Dunn’s test at α cut off 0.05.
bNonsignificant difference based on the multiple comparisons Dunn’s test at α cut off 0.05.
cNonsignificant difference based on the Wilcoxon matched-pairs signed-rank test at α cutoff 0.05.
Abbreviations: FSH, follicle-stimulating hormone; LH, luteinizing hormone.
Table 1. Baseline demographic, clinical, and previous treatment characteristics of the study patients, n (%)
Characteristics Active (n = 50), n (%) Placebo (n = 11), n (%) Total (n = 61), n (%)
Postmenopausal status
≥ 12 mo of spontaneous amenorrhea 44 (88.0) 11 (100.0) 55 (90.2)
≥ 6 wk postsurgical bilateral oophorectomya 5 (10.0) 0 (0.0) 5 (8.2)
6 mo of spontaneous amenorrhea with serum
FSH increased levels >40 mIU/mL
1 (2.0) 0 (0.0) 1 (1.6)
ECOG performance status
0 44 (88.0) 11 (100.0) 55 (90.2)
1 5 (10.0) 0 (0.0) 5 (8.2)
Not available 1 (2.0) 0 (0.0) 1 (1.6)
Breast Cancer Stage
I 18 (36.0) 4 (36.4) 22 (36.1)
IIA 23 (46.0) 3 (27.3) 26 (42.6)
IIB 7 (14.0) 2 (18.2) 9 (14.8)
IIIA 2 (4.0) 2 (18.2) 4 (6.6)
Estrogen receptor
Positive 50 (100.0) 11 (100.0) 61 (100.0)
Progesterone receptor
Negative 11 (22.0) 2 (18.2) 13 (21.3)
Positive 38 (76.0) 9 (81.8) 47 (77.0)
Not available 1 (2.0) 0 (0.0) 1 (1.6)
HER2
Negative 37 (74.0) 8 (72.7) 45 (73.8)
Positive 13 (26.0) 3 (27.3) 16 (26.2)
Adjuvant hormonal treatments
Aromatase inhibitors 41 (82.0) 10 (90.9) 51 (83.6)
Aromatase inhibitors + tamoxifen 8 (16.0) 1 (9.1) 9 (14.8)
Aromatase inhibitors + tamoxifen + LHRH
agonist
1 (2.0) 0 (0.0) 1 (1.6)
aIncluding patients with and without hysterectomy.
Abbreviations: ECOG, Eastern Cooperative Oncology Group; HER2, human epidermal growth factor receptor 2.
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Click here to access other published clinical trials.
Table 3. Patients reporting adverse events during treatment, n (%)
Adverse event Active (n = 50), n (%) Placebo (n = 11), n (%) Total (n = 61), n (%)
Reproductive system and breast disorders
Atrophic vulvovaginitis 1 (2.0) 1 (1.6)
Breast tenderness 1 (2.0) 1 (1.6)
Vaginal discharge 1 (2.0) 1 (1.6)
Vulvovaginal inflammation 1 (2.0) 1 (1.6)
Vulvovaginal pruritus 1 (2.0) 1 (1.6)
Musculoskeletal and connective tissue disorders
Back pain 1 (9.1) 1 (1.6)
Pain in extremity 1 (2.0) 1 (1.6)
Nervous system disorders
Burning sensation 1 (2.0) 1 (1.6)
Respiratory, thoracic and mediastinal disorders
Cough 1 (2.0) 1 (1.6)
Gastrointestinal disorders
Diarrhea 2 (4.0) 2 (3.3)
Vomiting 1 (2.0) 1 (1.6)
Infections and infestations
Gastroenteritis 1 (9.1) 1 (1.6)
Gastroenteritis viral 1 (2.0) 1 (1.6)
Influenza 1 (2.0) 1 (1.6)
Pharyngitis 1 (2.0) 1 (1.6)
Urinary tract infection 3 (6.0) 1 (9.1) 4 (6.6)
Viral upper respiratory tract infection 1 (2.0) 1 (1.6)
Vulvovaginal candidiasis 1 (9.1) 1 (1.6)
General disorders and administration site
conditions
Mucosal dryness 1 (2.0) 1 (1.6)
Polyp 1 (2.0) 1 (1.6)
Pyrexia 1 (2.0) 1 (1.6)
Ear and labyrinth disorders
Vertigo positional 1 (2.0) 1 (1.6)
None of the adverse events reported was severe enough to interrupt treatment with ultralow-dose 0.005% estriol vaginal gel.
In addition to the adverse events summarized in this table, one serious, nonrelated adverse event was reported in the active group: lymphoma.
The patient experienced fever and jaw pain (a sample of the lymph node was extracted to investigate the symptoms) before entering the study.
The result of the analysis, which was available after assigning the patient to the active group, revealed the presence of lymphoma, and the
patient was excluded from the study.
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